[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588939":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":350,"collaborators":33,"id":352,"slug":353,"hasResults":354,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":33,"eligibilityCriteria":358,"healthyVolunteers":354,"sex":359,"minAge":360,"maxAge":33,"enrollmentInfo":361,"targetDuration":33,"studyType":364,"phases":365,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":54,"whyStopped":33,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":391},{"fullName":5,"class":6},"TuHURA Biosciences, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm","EXPERIMENTAL","Participants randomized to the treatment arm will receive IFx-Hu2.0 (0.1 mg) via intralesional injection in a single lesion once per week for 3 consecutive weeks. Pembrolizumab (200 mg) will be administered intravenously (IV) on Day 1, followed by administration every 3 weeks during the first year of treatment. In the second year, the pembrolizumab dose will be 400 mg every 6 weeks. Pembrolizumab treatment will continue until progressive disease (PD), unacceptable immune-related toxicities, or for a maximum duration of 2 years.",[13,14],"Drug: IFx-Hu2.0","Drug: Pembrolizumab",{"label":16,"type":17,"description":18,"interventionNames":19},"Control Arm","PLACEBO_COMPARATOR","Participants randomized to the control arm will receive placebo (0.9% Sodium Chloride Injection, USP) via intralesional injection in a single lesion once per week for 3 consecutive weeks. Pembrolizumab (200 mg) will be administered IV on Day 1, followed by administration every 3 weeks during the first year of treatment. In the second year, the dose will be 400 mg every 6 weeks. Pembrolizumab treatment will continue until PD, unacceptable immune-related toxicities, or for a maximum duration of 2 years.",[20,14],"Drug: Placebo",[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","IFx-Hu2.0","Therapeutic Classification:\n\n• Innate immune agonist\n\nRoute of Administration:\n\n• Intralesional",[9],[28],"pAc\u002Femm55",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo","Route of Administration:\n\n• Intralesional",[16],null,{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Pembrolizumab","Therapeutic Classification:\n\n• Immunotherapy (Immune checkpoint inhibitor)\n\nRoute of administration:\n\n• Intravenous (IV) infusion",[16,9],[39],"KEYTRUDA",[41],{"name":42,"affiliation":43,"role":44},"Andrew S Brohl, MD","Collaborator","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":33,"email":50},"Amit Pande, MD","CONTACT","8138756600","clinicaltrials@tuhurabio.com",[52,71,87,103,120,135,151,167,184,200,217,233,250,267,284,301,317,334],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"USC Norris Comprehensive Cancer Center","RECRUITING","Los Angeles","California","90033","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-118.24368,34.05223,{"lat":64,"lon":63},[67,70],{"name":68,"role":48,"phone":33,"phoneExt":33,"email":69},"In Gino, MD","Gino.In@med.usc.ed",{"name":68,"role":44,"phone":33,"phoneExt":33,"email":33},{"facility":72,"status":54,"city":73,"state":56,"zip":74,"country":58,"countryCode":59,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"University of California San Francisco - Helen Diller Family Comprehensive Cancer Center","San Francisco","94143",{"type":61,"coordinates":76},[77,78],-122.41942,37.77493,{"lat":78,"lon":77},[81,85],{"name":82,"role":48,"phone":83,"phoneExt":33,"email":84},"Martha Arriaga","415-309-0105","Martha.Arriaga@ucsf.edu",{"name":86,"role":44,"phone":33,"phoneExt":33,"email":33},"Adil Daud, MD",{"facility":88,"status":54,"city":89,"state":56,"zip":90,"country":58,"countryCode":59,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Stanford Health Care - Skin Cancer Program","Stanford","94304",{"type":61,"coordinates":92},[93,94],-122.16608,37.42411,{"lat":94,"lon":93},[97,101],{"name":98,"role":48,"phone":99,"phoneExt":33,"email":100},"Phuong Pham","(650) 725-9810","ppham5@stanford.edu",{"name":102,"role":44,"phone":33,"phoneExt":33,"email":33},"Sunil Reddy, MD",{"facility":104,"status":54,"city":105,"state":106,"zip":107,"country":58,"countryCode":59,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"University of Colorado Hospital - Anschutz Cancer Pavilion","Aurora","Colorado","80045",{"type":61,"coordinates":109},[110,111],-104.83192,39.72943,{"lat":111,"lon":110},[114,118],{"name":115,"role":48,"phone":116,"phoneExt":33,"email":117},"Martin Parks","303-724-6240","MelanomaClinicalResearch@olucdenver.onmicrosoft.com",{"name":119,"role":44,"phone":33,"phoneExt":33,"email":33},"Theresa Medina, MD",{"facility":121,"status":54,"city":122,"state":123,"zip":124,"country":58,"countryCode":59,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Mayo Clinic Comprehensive Cancer Center","Jacksonville","Florida","32224",{"type":61,"coordinates":126},[127,128],-81.65565,30.33218,{"lat":128,"lon":127},[131,133],{"name":33,"role":48,"phone":132,"phoneExt":33,"email":33},"904-953-2000",{"name":134,"role":44,"phone":33,"phoneExt":33,"email":33},"Ruqin Chen, MD",{"facility":136,"status":54,"city":137,"state":123,"zip":138,"country":58,"countryCode":59,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Sylvester Comprehensive Cancer Center","Miami","33136",{"type":61,"coordinates":140},[141,142],-80.19366,25.77427,{"lat":142,"lon":141},[145,149],{"name":146,"role":48,"phone":147,"phoneExt":33,"email":148},"Kendal Payne","305-243-1084","CRScutaneous@miami.edu",{"name":150,"role":44,"phone":33,"phoneExt":33,"email":33},"Lynn Feun, MD",{"facility":152,"status":54,"city":153,"state":123,"zip":154,"country":58,"countryCode":59,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Moffitt Cancer Center","Tampa","33612",{"type":61,"coordinates":156},[157,158],-82.45843,27.94752,{"lat":158,"lon":157},[161,165],{"name":162,"role":48,"phone":163,"phoneExt":33,"email":164},"Inayaa Johnson","813-745-8336","inayaa.johnson@moffitt.org",{"name":166,"role":44,"phone":33,"phoneExt":33,"email":33},"Andrew Brohl, MD",{"facility":168,"status":54,"city":169,"state":170,"zip":171,"country":58,"countryCode":59,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":61,"coordinates":173},[174,175],-71.05977,42.35843,{"lat":175,"lon":174},[178,182],{"name":179,"role":48,"phone":180,"phoneExt":33,"email":181},"Aiden Bergin","617-632-6571","aidan_bergin@dfci.harvard.edu",{"name":183,"role":44,"phone":33,"phoneExt":33,"email":33},"Karam Khaddour, MD",{"facility":121,"status":54,"city":185,"state":186,"zip":187,"country":58,"countryCode":59,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Rochester","Minnesota","55905",{"type":61,"coordinates":189},[190,191],-92.4699,44.02163,{"lat":191,"lon":190},[194,198],{"name":195,"role":48,"phone":196,"phoneExt":33,"email":197},"Madalyn Helvig","507-266-9955","helvig.madalyn@mayo.edu",{"name":199,"role":44,"phone":33,"phoneExt":33,"email":33},"Tassos Dimou, MD",{"facility":201,"status":54,"city":202,"state":203,"zip":204,"country":58,"countryCode":59,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":61,"coordinates":206},[207,208],-74.04347,40.88593,{"lat":208,"lon":207},[211,215],{"name":212,"role":48,"phone":213,"phoneExt":33,"email":214},"Nicole Caltabellotta","551-996-1777","OncologyResearchReferral@hmhn.org",{"name":216,"role":44,"phone":33,"phoneExt":33,"email":33},"Andrew Pecora, MD",{"facility":218,"status":54,"city":219,"state":203,"zip":220,"country":58,"countryCode":59,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Atlantic Health System","Morristown","07960",{"type":61,"coordinates":222},[223,224],-74.48154,40.79677,{"lat":224,"lon":223},[227,231],{"name":228,"role":48,"phone":229,"phoneExt":33,"email":230},"Maureen Nowakowski","973-971-5569","maureen.nowakowski@atlantichealth.org",{"name":232,"role":44,"phone":33,"phoneExt":33,"email":33},"Eric Whitman, MD",{"facility":234,"status":54,"city":235,"state":236,"zip":237,"country":58,"countryCode":59,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"East Carolina University","Greenville","North Carolina","27834",{"type":61,"coordinates":239},[240,241],-77.36635,35.61266,{"lat":241,"lon":240},[244,248],{"name":245,"role":48,"phone":246,"phoneExt":33,"email":247},"Shahana Patel","252-744-5418","patelsha22@ecu.edu",{"name":249,"role":44,"phone":33,"phoneExt":33,"email":33},"Nasreen Vohra, MD",{"facility":251,"status":54,"city":252,"state":253,"zip":254,"country":58,"countryCode":59,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"UPMC Hillman Cancer Center","Pittsburgh","Pennsylvania","15232",{"type":61,"coordinates":256},[257,258],-79.99589,40.44062,{"lat":258,"lon":257},[261,265],{"name":262,"role":48,"phone":263,"phoneExt":33,"email":264},"Kaitlin Bocian","412-623-4115","Bocianka2@upmc.edu",{"name":266,"role":44,"phone":33,"phoneExt":33,"email":33},"Melissa Burgess, MD",{"facility":268,"status":54,"city":269,"state":270,"zip":271,"country":58,"countryCode":59,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77384",{"type":61,"coordinates":273},[274,275],-95.36327,29.76328,{"lat":275,"lon":274},[278,282],{"name":279,"role":48,"phone":280,"phoneExt":33,"email":281},"Shawnee Carpenter","713-792-6363","scarpenter@mdanderson.org",{"name":283,"role":44,"phone":33,"phoneExt":33,"email":33},"Neal Akhave, MD",{"facility":285,"status":54,"city":286,"state":287,"zip":288,"country":58,"countryCode":59,"cosmosGeoPoint":289,"geoPoint":293,"contacts":294},"Inova Schar Cancer","Fairfax","Virginia","22031",{"type":61,"coordinates":290},[291,292],-77.30637,38.84622,{"lat":292,"lon":291},[295,299],{"name":296,"role":48,"phone":297,"phoneExt":33,"email":298},"Stephanie Bebber","571-472-4724","Stephanie.vanbebber@inova.org",{"name":300,"role":44,"phone":33,"phoneExt":33,"email":33},"Jafar Al-Mondhiry, MD",{"facility":302,"status":54,"city":303,"state":287,"zip":304,"country":58,"countryCode":59,"cosmosGeoPoint":305,"geoPoint":309,"contacts":310},"Virginia Commonwealth University","Richmond","23298",{"type":61,"coordinates":306},[307,308],-77.46026,37.55376,{"lat":308,"lon":307},[311,315],{"name":312,"role":48,"phone":313,"phoneExt":33,"email":314},"Jon Radar","804-828-1545","raderjp2@vcu.edu",{"name":316,"role":44,"phone":33,"phoneExt":33,"email":33},"Andrew Poklepovic, MD",{"facility":318,"status":54,"city":319,"state":320,"zip":321,"country":58,"countryCode":59,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109",{"type":61,"coordinates":323},[324,325],-122.33207,47.60621,{"lat":325,"lon":324},[328,332],{"name":329,"role":48,"phone":330,"phoneExt":33,"email":331},"Maya Yousefiasl","206-606-7172","maryamyo@fredhutch.org",{"name":333,"role":44,"phone":33,"phoneExt":33,"email":33},"Shailender Bhatia, MD",{"facility":335,"status":54,"city":336,"state":337,"zip":338,"country":58,"countryCode":59,"cosmosGeoPoint":339,"geoPoint":343,"contacts":344},"West Virginia University","Morgantown","West Virginia","26506",{"type":61,"coordinates":340},[341,342],-79.9559,39.62953,{"lat":342,"lon":341},[345,348],{"name":346,"role":48,"phone":33,"phoneExt":33,"email":347},"Meg Zafiris","margaret.zafiris@hsc.wvu.edu",{"name":349,"role":44,"phone":33,"phoneExt":33,"email":33},"Joanna Kolodney, MD",{"type":351,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100588939","phase-2-placebo-controlled-trial-of-ifx-hu20-followed-by-pembrolizumab-in-checkpoint-inhibitor-nave-participants-with-advanced-or-metastatic-merkel-cell-carcinoma-100588939",false,"NCT06947928","Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Life expectancy equal to or greater than six months.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status \\\u003C 2.\n4. Must be recurrent and\u002For unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have histologically confirmed Merkel cell carcinoma\n\n   1. Must have at least one injectable lesion equal to or greater than 3 mm.\n   2. Must have measurable disease as defined by RECIST v1.1.\n5. Participants should be CPI naïve i.e., no prior therapy with CPI including but not limited to Pembrolizumab, avelumab, ipilimumab, nivolumab.\n6. Tumor tissue from an archival core biopsy or resected site of disease must be provided for biomarker analyses. If archival tissue is not available, then a new biopsy should be performed.\n7. Adequate hematological, hepatic, and renal function according to laboratory ranges and medical criteria defined within the study protocol.\n\nExclusion Criteria:\n\n1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with protocol requirements.\n2. Participants with known active brain metastases with the exception of treated brain metastases that have imaging proving stability at least 4 weeks prior to the start of study treatment, no new metastases, and not requiring steroids.\n3. Participants with recurrent resectable MCC\n4. Participants with prior systemic chemotherapy\n5. Pregnant or breastfeeding females and females desiring to become pregnant or breastfeed within the timeframe of this study.\n6. Active, known, or suspected autoimmune disease. Potential Participants with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. Low-grade autoimmune toxicity is NOT an exclusion under this criterion.\n7. A condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.","ALL","18 Years",{"count":362,"type":363},118,"ESTIMATED","INTERVENTIONAL",[366,367],"PHASE2","PHASE3","This Phase 2\u002F3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.",[370],"Advanced Or Metastatic Merkel Cell Carcinoma",[372,373,374,375,376,377,378,379,380,381],"Merkel Cell Carcinoma","Advanced","Metastatic","MCC","pembrolizumab","Innate Immune Agonist","Skin Cancer","X-Mark","X Mark","Rare Skin Cancers","2026-04-14",{"date":384,"type":385},"2026-04-17","ACTUAL",{"date":387,"type":385},"2025-12-11",{"date":389,"type":363},"2032-12-30",{"name":5,"class":6},18]